Soft-tissue sarcoma of an arm or leg (extremity) is usually treated with surgery, sometimes followed by radiation therapy. Adding chemotherapy to this treatment combination may further reduce the risk of recurrence and help facilitate a better surgery.
Gemcitabine and docetaxel are chemotherapy drugs used in the standard treatment of soft-tissue sarcoma. However, sometimes the tumor returns despite these drugs. Pazopanib is a drug approved for treating kidney cancer that has shown promise in phase II and III clinical trials for the treatment of advanced sarcoma.
The purpose of this study is to determine if adding pazopanib to standard chemotherapy (gemcitabine and docetaxel) will reduce the risk of cancer recurrence after surgery. In addition, the study will identify the dose of pazopanib that can be given safely with gemcitabine and docetaxel in patients with soft-tissue sarcoma who receive this combination chemotherapy before surgery.